Resatorvid (TAK-242) is a cyclohexane derivative that was invented by scientists at Takeda in a drug discovery campaign to identify inhibitors of the receptor TLR4.

[2] A randomized, double-blinded Phase III trial of resatorvid in sepsis was halted early due to lack of efficacy, and the compound has become a widely used tool compound in biological research.

[5] Efforts have been made to improve resatorvid by making prodrugs and deuterated derivatives.

[3] This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.